Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial.
Brian Andrew Van TineAnders Krarup-HansenLisa M HessAlbiruni R Abdul RazakVictoria SoldatenkovaJennifer WrightSe Hoon ParkPublished in: Rare tumors (2022)
Patients with advanced or metastatic sarcoma reported a relatively rapid decline in PROs during doxorubicin-based treatment, with patients with poorer symptoms at baseline (specifically fatigue), subsequently receiving less doxorubicin therapy. The availability of detailed summary data from the patient perspective during doxorubicin-based treatment may inform future care of these patients and can provide a resource for the development of PRO endpoints in future trials.
Keyphrases
- clinical trial
- phase iii
- drug delivery
- cancer therapy
- open label
- end stage renal disease
- newly diagnosed
- healthcare
- squamous cell carcinoma
- palliative care
- current status
- small cell lung cancer
- phase ii
- sleep quality
- ejection fraction
- stem cells
- peritoneal dialysis
- case report
- electronic health record
- quality improvement
- bone marrow
- depressive symptoms
- deep learning
- health insurance
- loop mediated isothermal amplification